Please upgrade your browser.
Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma (RCC), failed to meet the prespecified criteria for use or continued development.
Researchers identified two protein biomarkers— aquaporin-1 (AQP1) and perlipin-2 (PLIN2)— that were more than 95 percent accurate in detecting early-stage kidney cancers. The tests also didn’t result in any false-positives caused by non-cancerous kidney disease.
The seven-year study began in 2007 and the findings revolutionized the standard protocol for patient management in NCCS with an attenuated-dose regimen of sunitinib for patients with mRCC.
Obesity is one of the leading risk factors for developing renal cell carcinoma, an immunogenic tumor that is treated clinically with immunostimulatory therapies. Currently, however, the mechanisms linking obesity with renal cancer incidence are unclear.
Professor Beech said: "This unexpected discovery is exciting because it means we could develop new cancer drugs towards these particular proteins, TRPC4 and TRPC5.
Renal cell carcinoma (RCC) incidence rates are higher in developed countries, where up to half of the cases are discovered incidentally. Declining mortality trends have been reported in highly developed countries since the 1990s.
This study will explore the effectiveness of the experimental drug known as CRLX101 combined with bevacizumab (Avastin), in patients with metastatic renal cell carcinoma (RCC).
How does exercise benefit cancer patients? It turns out that there are a number of different reasons why exercise has such a positive impact on cancer patients. The immune system becomes more activated during exercise...
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma...
Novartis has completed a series of transactions with GlaxoSmithKline (GSK), including the acquisition of certain oncology products and pipeline compounds from GSK, the creation of a world-leading consumer healthcare business through a joint venture...
|Powered by NeonCRM|